Kornimate/medical-research-clean huggingface dataset:
preoperative oral supplementation with branched-chain amino acids (bcaa) improves postoperative quality of life

Conditions: Hepatocellular Carcinoma; Chronic Liver Disease

Summary: the aims of this study are (1) to study the benefit of branched-chain amino acids enriched nutrient-mixture by analyzing a variety of clinical parameter, including laboratory data, the duration of hospitalization after the surgery, and (2) to investigate the postoperative quality of life (qol) in receiving peri-operatively branched-chain amino acids enriched nutrient-mixture in patients who undergone the hepatic management for hepatocellular carcinoma (hcc) with chronic liver disease.

patients with cirrhosis of the liver complicated with hcc are often in a state of protein energy malnutrition. a limited number of studies have indicated an important role for nutritional support in the surgical management of patients who have undergone hepatic resection for hcc. in a preliminary study, we reported the clinical efficacy of supplementation with branched-chain amino acids in a small number of patients with liver cirrhosis who underwent hepatic surgery for hcc. the aims of this study are (1) to study the benefit of branched-chain amino acids enriched nutrient-mixture by analyzing a variety of clinical parameter, including laboratory data, the duration of hospitalization after the surgery, and (2) to investigate the postoperative qol in receiving peri-operatively branched-chain amino acids enriched nutrient-mixture in patients who undergone the hepatic management for hcc with chronic liver disease.

Eligibility criteria:
inclusion criteria: * patients who underwent elective liver resection for the treatment of hepatocellular carcinoma or adenocarcinoma with chronic liver diseases. exclusion criteria: * body weight loss greater than 10 per cent during the 6 months prior to surgery, * the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal or heart disease.

Keywords: qol liver
an examination of the safety and blood pressure lowering effect of increasing doses of benicar® and benicar® hct in patients with hypertension

Conditions: Hypertension

Summary: effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension


Eligibility criteria:
inclusion criteria: * 1. 18 years of age. * 2. patients with stage ii systolic hypertension * 3. if female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study. exclusion criteria: * 1. hypertensive encephalopathy, stroke or transient ischemic attack (tia) within the past 6 months. 2. history of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months. 3. severe hypertension (dbp greater than or equal to 110 mm hg or sbp \> 200 mm hg). 4. history of secondary hypertension including renal disease, phaeochromocytoma, or cushing's disease. 5. type i diabetes mellitus. 6. evidence of symptomatic resting bradycardia, congestive heart failure, or hemodynamically significant cardiac valvular disease. 7. presence of heart block greater than first degree sinoatrial block, wolff-parkinson-white syndrome, sick sinus syndrome, atrial fibrillation, or atrial flutter. 8. laboratory test values considered clinically significant by the investigator. 9. evidence of liver disease as indicated by sgot or sgpt and/or total bilirubin \> 3 times the upper limit of normal. 10. pregnant or lactating females. * 11. patients with malignancy during the past 5 years excluding squamous cell or basal cell carcinoma of the skin.

Keywords: systolic hypertension, angiotensin receptor blocker
early postoperative fitting of the air- limb prosthesis for transtibial amputees

Conditions: Vascular Diseases

Summary: the aim of the study is to check whether an early adjustment of the air-limb prosthesis to transtibial amputees due to vascular diseases, will shorten the healing time of the stump and the process of rehabilitation.

the method of immediate adjustment of a temporary prosthesis has been developed in the past, aiming to reduce the healing time of the stump and the process of rehabilitation. according to this method, a temporary prosthesis is being adjusted immediately after amputation, or during the first week after it. rehabilitation starts with the patient's standing while partial weight bearing on the prosthesis. in spite of many experiments and trials to adopt this process of rehabilitation, it is not universally adopted, because of the bad adjustment and damages to the stump caused by the plaster of paris. at present, with the improvement of materials and research experiments are being renewed, to check the efficiency of the process, using the air- limb a temporary prosthesis.

Eligibility criteria:
inclusion criteria: * transtibial amputees due to vascular diseases. exclusion criteria: * bilateral amputation. * upper extremity can't bear weight. * the sound leg can't bear weight. * amputee that needs dialysis treatment. * cognitive impairment.

Keywords: transtibial amputees due to vascular diseases.
the effect evaluation of laser acupuncture in obesity

Conditions: Obesity

Summary: a randomized double-blind placebo-controlled crossover trial is conducted. 200 subjects aged above 20 years with body mass index (bmi) more than 25 kg/m2 are randomly divided into 2 groups (group 1 and group 2). group 1 receives laser acupuncture therapy first while group 2 receives sham laser acupuncture therapy first. after 12 weeks of treatment and 14 days of washout, group 1 switch to sham laser acupuncture therapy while group 2 switch to laser acupuncture for 12 weeks. the subjects are treated with a gallium aluminum arsenide handylaser trion, which is used to apply at each of the acupuncture points for 10 seconds every time, 3 times per week. the measurements of outcomes are performed in the beginning, weekly during treatment, and monthly after treatment for 3 months.


Eligibility criteria:
inclusion criteria: * body mass index over 25 kg/m2 or waist girth over 80cm in female, waist girth over 90cm in male exclusion criteria: * pathmakers user * epilepsy history * pregnancy * immuno-inhibiting agents user * malignancy * skin contacted disease * weight controlled agents user during trial period * eating disorder

Keywords: laser acupuncture obesity
da-vinci sp versus xi thyroid surgery

Conditions: Thyroid Cancer; Thyroid Nodule

Summary: one year comparative analysis between spra\* versus baba\*\* thyroid surgery. \* spra: da-vinci sp robotic areolar approach thyroid surgery \*\* baba: da-vinci xi robotic bilateral. axillary breast approach thyroid surgery

study design: retrospective data analysis study period: december 2022 to december 2023 candidate: patients who received robot thyroid surgery during study period numbers of candidates: total of 270 patients group : spra (n=111) versus baba (n=159) statistic analysis: t-test for continuous variable, fisher's exact test for categorical variable

Eligibility criteria:
inclusion criteria: * patients who received robot thyroid surgery in our institution * retrospective review exclusion criteria: * n/a

Keywords: thyroid robotic surgical procedures minimally invasive surgical procedures
acetyl-l-carnitine in severe hepatic encephalopathy

Conditions: Hepatic Encephalopathy (Grade 3 of the West Haven Grading Scale)

Summary: to assess the clinical efficacy of alc in the treatment of severe hepatic encephalopathy (grade 3 of the west haven grading scale), we performed a randomised, double blind placebo-controlled study administering alc to cirrhotic patients, evaluating the effects on ammonia levels and performance in cognitive functions.


Eligibility criteria:
inclusion criteria: * patients with severe hepatic encephalopathy (grade 3 of the west haven grading scale) with hepatic cirrhosis exclusion criteria: * patients with a history of recent alcohol abuse, patients using psychotropic drugs (e.g., antipsychotics, interferon, benzodiazepines, anti-epileptics, sedatives and antidepressants) * other exclusion criteria were the following: major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syndrome or bacterial peritonitis; acute superimposed liver injury;patients with metabolic disorders such as diabetes mellitus, unbalanced heart failure and/or respiratory failure or end-stage renal disease; any additional precipitating factors such as high protein intake (additional high-protein meals), constipation; illiteracy.
study of rhpro-uk in patients with acute ischaemic stroke in 4.5 hours after stroke onset(prost)

Conditions: Acute Ischaemic Stroke

Summary: this is a randomized, rt-pa controlled, open-label phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhpro-uk) versus rt-pa thrombolysis for patients with acute ischaemic stroke in 4.5 hours after stroke onset.


Eligibility criteria:
inclusion criteria: 1. ischemic stroke with symptoms of neurological deficits. 2. aged 18 to 80 years（including the critical value）. 3. nih stroke scale（nihss）scores of 4 to 25（including the critical value）. 4. treatment within 4.5 hours after stroke onset. 5. the symptoms of stroke last at least 30 minutes without significant improvement before treatment. 6. ct showed negative or signs of early infarction. 7. informed consent form signed by the patients or family (legal representatives) must be provided. exclusion criteria: 1. patients with premorbid modified rankin scale (mrs) score ≥2 2. ct showed multiple infarctions（low density\> 1/3 cerebral hemisphere）. 3. transient ischemic attack. 4. epileptic seizure after stroke. 5. intracranial tumor, arteriovenous malformation and aneurysm. 6. iatrogenic stroke. 7. planned for thrombectomy. 8. cardioembolism and atrial fibrillation. 9. myocardial infarction history within 3 months. 10. severe cerebral trauma or stroke history within 3 months. 11. patients with systolic blood pressure ≥ 180mmhg or diastolic blood pressure ≥ 100mmhg after anti-hypertension treatment. 12. intracranial hemorrhage or subarachnoid hemorrhage on baseline. 13. active visceral hemorrhage. 14. patients with intracerebral hemorrhage history. 15. patients with diabetic retinopathy history. 16. puncture in 1 week which can not be oppressed. 17. major surgery or severe trauma within 2 weeks. 18. intracranial surgery, intraspinal surgery or solid organ biopsy within 30 days. 19. heparin treatment within 48h and increased aptt is above uln. 20. using of oral anticoagulant drugs and pt \>15s or inr \>1.7. 21. high risk of acute hemorrhage include platelet count\<10\^9/l. 22. using of thrombin inhibitors or factor xa inhibitor with abnormal results of sensitive laboratory examination. 23. blood glucose \ 22.2 mmol/l. 24. pregnancy, lactating or menstrual women. 25. the investigator believes that the patient is not suitable for the study.
depth of epinephrine delivery with auto-injectors devices

Conditions: Anaphylactic Shock

Summary: anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. although there are several causes of fatal anaphylaxis, food allergy is one of the most common. epinephrine is recommended as the initial treatment of choice for anaphylaxis. a delay in epinephrine administration may contribute to an increased risk of death. therefore, the world allergy organization recommends that, for the treatment of anaphylaxis, epinephrine solution be administered intramuscularly in the mid-anterolateral thigh. in france 3 auto-injector pens are available: anapen®, epipen® and jext®. for weight\> 30 kg, the devices have a needle size respectively of 7.49 mm, 15.02 mm and 15.36 mm. for the weights between 15 and 30 kg needle size is 7.49 mm to 12.7 mm and anapen® for epipen® and jext®. several studies suggest that the needle length needle is sometim


Eligibility criteria:
inclusion criteria: * a weight of over 30 kg at baseline * with food or an hymenoptera venom allergy (diagnosed by skin tests or serum-specific ige testing, requiring prescription epinephrine auto-injector pen according to european recommendations, exclusion criteria: * having a skin lesion on the lateral aspect of the thigh, * with a known or suspected allergy to the contact gel
cpb for arthroscopic hip surgery

Conditions: Acute Pain; Opioid Use

Summary: arthroscopic hip surgery is being increasingly performed to treat both intraarticular and extraarticular hip diseases. despite the minimally invasive approach, patients undergoing arthroscopic hip surgery still suffer severe pain due to the complex nature of hip innervation. postoperative pain reduces patient satisfaction and delay patient recovery and discharge. the efficacy of regional anesthesia techniques in postoperative pain management have been proved in various surgeries. however, it remains controversial whether or not peripheral nerve blocks can significantly improve postoperative analgesia after hip arthroscopy. several studies have shown that the fascia iliac block cannot improve postoperative analgesia for hip arthroscopy because it blocks only some branches of the lumbar plexus but not the sacral plexus. circum-psoas block (cpb) which has been defined in recent years is able to block the lumbar plexus nerves as well as sacral plexus such as the sciatic, superior gluteal, and inferior gluteal nerves. therefore, the investigators predict that it can provide effective postoperative analgesia for hip arthroscopy. in this study, the researchers aim to investigate the effectiveness of cpb in hip arthroscopy.


Eligibility criteria:
inclusion criteria: * primary unilateral ambulatory hip arthroscopy * age 18 to 70 years * asa physical status i to iii * ability to follow the protocol. exclusion criteria: * age \ 70 years of age * bmi above 40 * contraindications to peripheral nerve blockade * pregnancy * chronic pain condition requiring opioid intake at home * allergy to opioids or local anesthetics * patient refusal
adherence of diuretics in pulmonary hypertension

Conditions: Precapillary Pulmonary Hypertension

Summary: in this prospective study, the investigators will implement a systematic assessment of adherence to diuretics in a cohort of patients with precapillary pulmonary hypertension. this study is designed to: * determine the overall adherence rates for diuretic regimen * determine the determinants of non-adherence to diuretics * assess the risk of ph worsening occurrence in the non-adhesion group

introduction precapillary pulmonary hypertension (ph) is characterized by remodeling of small pulmonary arteries leading to a progressive increase in pulmonary vascular resistance (pvr) resulting to right heart failure and ultimately death. the prognosis of ph is closely related to the ability of the right ventricle to adapt to the progressive increase in pvr. the occurrence of acute right ventricular decompensation is associated with a very poor prognosis at short term. the management of precapillary ph is based on specific therapies combined with general measures and supportive therapies. diuretic treatment is recommended in pah patients with signs of rv failure and fluid retention (recommendation class i, level of evidence c). the beneficial effect of diuretics is probably essential for preventing episodes of acute right ventricular decompensation. however, no study analyzed the rate of adherence to diuretic regimen in ph patients and the impact of patterns of adherence to diuretics on the outcomes of patients. aim and objectives the main objectives of this study are to: * determine the overall adherence rates for diuretic regimen * determine the determinants of non-adherence to diuretics * assess the risk of ph worsening occurrence in the non-adherence group methodology evaluation of subjects and adhesion to diuretics at inclusion are recorded: * self-questioning of medication adherence: girerd questionnaire * assessment of the medication possession ratio * social and demographic data * comorbidities * ph characteristics * clinical evaluation: dyspnea assessed by nyha functional class (new york heart association functional classification : i-iv), signs of right heart failure * type of treatment regimen * history of serious events including non-programmed hospitalization for ph and/or worsening of the disease (15% reduction in the 6-minute walking test and worsening of the who functional class) and/or the need to reinforce specific ph therapies

Eligibility criteria:
inclusion criteria: * men and women over 18 years old * precapillary ph * diuretics treatment for at least 12 months * having given his/her non-opposition to participate exclusion criteria: * treatment regimen without diuretics * diuretics treatment for less than 12 months * postcapillary ph * people refusing or unable to give informed consent * no affiliation to a regime of social security. * protected patients

Keywords: pulmonary hypertension right heart failure adherence diuretics
effects of kinesiotaping vs.auricular therapy in primary dysmenorrhoea.

Conditions: Primary Dysmenorrhoea

Summary: this study analyse the effectiveness of auricular therapy vs. kinesio tape treatment for pain management of women with primary dysmenorrhoea.

pharmacological treatments are not effective for all women and therefore, the objective of this study was to assess and compare the effectiveness of kinesio tape and auricular therapy to decrease pain and drug intake in women with primary dysmenorrhoea. a randomized controlled trial was conducted. 114 university women from 18 to 30 years old were randomized to 5 groups: control, kinesio tape, placebo kinesio tape, auricular therapy and placebo auricular therapy. the study was carried out during 4 menstrual cycles of pre-treatment phase, 4 menstrual cycles of treatment phase and two follow up phases (first and third cycle after the treatments were completed). during the treatment phase, the techniques were applied during 72h in each cycle. the primary outcome measures were: mean pain intensity of the 3 first days of bleeding, maximum pain intensity, number of painful days and dose of drug intake measured with the visual analogue scale.

Eligibility criteria:
inclusion criteria: * women between 18 and 30 years old affected by primary dysmenorrhoea grade 2 and 3 of andersch y milsom classification (andersch y milsom, 1982), to have attended gynaecologist consultation for a general revision in the last 2 years, to have menstrual pain, to have regular menstrual cycles of 21 to 38 days, to not have an intrauterine/inter-uterine) device or to be on oral contraceptive treatment. exclusion criteria: * to have been diagnosed with a condition that could influence menstrual pain perception, to know or have been previously treated with the techniques used in the interventions and pregnancy.

Keywords: auricular therapy kinesio tape
sensitivity and specificity of 3 solutions of allergen extract for diagnosis by skin prick testing

Conditions: Allergy

Summary: a phase iii study to determine the sensitivity and specificity of three solutions of different allergen extracts for diagnosis by skin prick-test: * 5 grasses pollen, * birch pollen, * dermatophagoides pteronyssinus mite


Eligibility criteria:
inclusion criteria: * written informed consent to participate in the study * male or female subjects aged 5-60 years inclusive * female of childbearing potential must be on a reliable method of contraception and have a negative urine pregnancy test * presence of a clinical history of allergy: seasonal or perennial rhinitis, conjunctivitis and/or asthma during grass or birch pollen seasons (at least two pollen seasons) and/or due to mite exposure (at least two years) * subjects affiliated to a social security system exclusion criteria: * pregnant or breastfeeding women * dermographism * absence of cutaneous reactivity * presence of cutaneous lesions on the forearms either preventing the performance of the test or potentially interfering with the interpretation of the test * subjects presenting unstable asthma or poor general health condition * subjects with past or current specific immunotherapy treatment for any of the 3 tested allergens (grass, birch pollens, d. pteronyssinus and/or d. farinae mites) in the previous 5 years * any oral antihistaminic treatment in the previous 3 days or 10 days in case of loratadine or desloratadine * subjects on anti-ige treatment * subjects treated with beta-blockers and/or anti-depressives. * subjects currently participating in another clinical trial or still in exclusion period for a previous clinical trial * investigators, co-investigators, as well as their children or spouses and all the study collaborators * subjects under protection of the courts, legal guardianship or legal trusteeship
comparison of nn1250 plus insulin aspart with insulin detemir plus insulin aspart in type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in asia, europe, japan and south america. the aim of the trial is to compare the efficacy, safety and tolerability of nn1250 (insulin degludec (\[deg\]) with insulin detemir (idet), both combined with insulin aspart. the main period is registered internally at novo nordisk as nn1250-3585 while the extension period is registered as nn1250-3725.


Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus for at least 12 months * current treatment with any basal bolus insulin for at least 12 months * hba1c below or equal to 10.0% * body mass index (bmi) below or equal to 35.0 kg/m\^2 * for japan only: minimum age is 20 years * for the extension trial only: completed the six-month treatment period in trial nn1250-3585 (nct01074268) exclusion criteria: * use of any other antidiabetic drug than insulin within the last 3 months * cardiovascular disease within the last 6 months * uncontrolled treated/untreated severe hypertension * recurrent severe hypoglycemia or hypoglycemic unawareness or hospitalisation for diabetic ketoacidosis during the previous 6 months * pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures * cancer and medical history of cancer